Analystreport

BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity.

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report